Jadoul M,Bieber BA,Martin P,Akiba T,Nwankwo C,Arduino JM .2019 .Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int, 95 : 939-47.
Annex W. .2021 .Global progress report on HIV, viral hepatitis, and sexually transmitted infections. , : .
Organization WH . .. Global hepatitis report 2017., : .
Toyoda H,Kikuchi K. .2023 .Management of dialysis patients with hepatitis C virus in the era of direct‐acting antiviral therapy. Ther Apher Dial, 27 : 831-8.
Yu ML,Huang CF,Wei YJ,Lin WY,Lin YH,Hsu PY .2021 .Establishment of an outreach, grouping healthcare system to achieve micro elimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut, 70 : 2349-58.
Hu TH,Su WW,Yang CC,Yang CC,Kuo WH,Chen YY .2021 .Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan. AJKD, 78 : 511-9.
Huang CF,Chen GJ,Hung CC,Yu ML .2023 .HCV Micro elimination for High-risk Special Populations. J Infect Dis, 228 : 168-79.
Maruyama A,Partovi N,Yoshida EM,Erb SR,Azalgara VM,Hussaini T. .2017 .A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrol Dial Transpl, 32 : 35-41.
Cheema SS,Tauseef A,Fatima M,Iqbal MD,Khurshid S.,One Year Mortality .2023 .Reinfection Rate of Hepatitis C Among Patients on Hemodialysis after Successful DirectActing Antiviral Treatment. Medical Forum Monthly, 34 : 107-11.
Liu CH,Peng CY,Kao WY,Yang SS,Shih YL,Lin CL .2022 .Hepatitis C virus reinfection in patients on hemodialysis after achieving sustained virologic response with antiviral treatment. Alim Pharmacol Therap, 55 : 434-45.
Marc L,Mihaescu A,Lupusoru R,Schiller O,Bob F,Chisavu L .2023 .Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy-experience of 10 Romanian HD centers. Int Urol Nephrol, 55 : 2951-8.
Kashani M,Karimi M,Sharifi Rayeni A,Azizi Nadian MA,Mortezazadeh M,Parsaei A,Abolghasemi N .2024 .Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study. Front Med, 11 : 1460372.
Czarnecka P,Czarnecka K,Tronina O,Bączkowska T,Wyczałkowska-Tomasik A,Durlik M .2023 .Evaluation of longterm outcomes of direct acting antiviral agents in chronic kidney disease subjects: A single center cohort study. J Clin Med, 12(3513) : 8.
Shaibani B,Ayad K,Melodi M,Albarasi S,Annajar B,Jibani M. .2022 .Outcome of Treatment for Hepatitis C Infection in Hemodialysis Patients with Direct-Acting Second-Generation anti-HCV Drugs at Azzawiyah Kidney Hospital, Libya. Lib J Med Sci, 6 : 53-7.
Rossato G,Tovo CV,Almeida PRL .2020 .Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes. Braz J Infect Dis, 24 : 25-9.
Agarwal SK,Bagchi S,Yadav RK .2017 .Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. Kidney Int Rep, 2 : 831-5.
Bunchorntavakul C,Maneerattanaporn M,Chavalitdhamrong D. .2015 .Management of patients with hepatitis C infection and renal disease. World J Hepatol, 7 : 213-8.